Table 3.

Estimated change from baseline to each follow-up time point in patients in the 50 μg dose.

	(T1) to T2	(T1) to T3	(T1) to T4
CD4 FoxP3+	0.16; p=0.61	-0.01; p=0.98	0.16; p=0.63
CD8+nv	8.07; p=0.003	6.75; p=0.01	5.69; p=0.03
CD8+GzmB+	-5.43; p=0.02	-4.85; p=0.03	-5.17; p=0.03
CD8+Tem	-2.71; p=0.004	-2.13; p=0.01	-1.27; p=0.14
CD8+TEMRA	-4.01; p=0.04	-3.8; p=0.06	-4.4; p=0.04
CD8+Prf+	-1.22; p=0.08	-1.5; p=0.04	-1.38; p=0.07
CD8+Tcm	-1.44; p=0.20	-1.22; p=0.27	-0.6; p=0.61
CD4+nv	6.01; p=0.04	6.49; p=0.03	2.28; p=0.42
CD4+Tem	-3.1; p=0.07	-3.29; p=0.05	-0.66; p=0.70
CD4+TEMRA	-2.24; p=0.05	-2.26; p=0.05	-1.81; p=0.13
CD4+GzmB+	-2.05; p=0.06	-2.25; p=0.04	-1.57; p=0.17
CD4+Tcm	-0.91; p=0.51	-0.84; p=0.54	0.03; p=0.98

The estimated difference and p-value were calculated using a mixed effects model with a random intercept. Positive estimated differences indicate that the mean level of the marker increased after administration of the treatment. Bold entries had a p-value less than 0.05.